Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

SAFFRON Trial Results Show Significant Improvements in PFS and OS

Dr. Shun Lu reported data from the global phase III trial that may establish a new standard of care for patients with EGFR-mutant NSCLC with MET overexpression or amplification after disease progression.

Haleigh Behrman

Estimated Read Time:

3–4 minutes

Meeting News

Despite advances in first-line therapy, most patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) eventually experience disease progression.

Shun Lu, MD, PhD
Shun Lu, MD, PhD

MET dysregulation is a key mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs), with MET protein overexpression and/or gene amplification reported in about 34% of patients treated with osimertinib, highlighting an unmet need among patients with limited treatment options and poorer outcomes.

Osimertinib in combination with savolitinib has previously demonstrated clinically meaningful and durable responses in the phase II SAVANNAH trial, as well as improvements in progression-free survival (PFS) compared with chemotherapy in the phase III SACHI study.

In the global phase III SAFFRON study, the combination of osimertinib and savolitinib yielded statistically significant improvements in overall survival (OS) and PFS in patients with EGFR-mutant advanced NSCLC with MET overexpression or amplification after prior treatment with osimertinib.

The trial evaluated the efficacy and safety of osimertinib plus savolitinib versus platinum-based pemetrexed chemotherapy in patients with EGFR-mutant advanced NSCLC with MET overexpression and/or amplification after progression on osimertinib.

Shun Lu, MD, PhD—who presented the data at the 2026 European Society for Medical Oncology Congress—said they support osimertinib combined with savolitinib as an effective oral targeted treatment option for this patient population.

The trial enrolled 338 patients with EGFR-mutant locally advanced or metastatic NSCLC who had MET overexpression and/or amplification and had progressed on osimertinib.

Patients were randomly assigned to receive 80 mg of osimertinib once daily and 300 mg of savolitinib twice daily (n = 171) or platinum-pemetrexed (n = 167) every three weeks for four cycles, followed by maintenance pemetrexed every three weeks until disease progression or discontinuation.

The primary endpoint was PFS assessed by Blinded Independent Central Review (BICR), while secondary endpoints included OS, investigator-assessed PFS, and safety. Patient demographics were well balanced between the treatment arms, in terms of gender, age, race, and other factors.

Median BICR-assessed PFS was 7.6 months for those treated with osimertinib plus savolitinib, compared with 5.4 months for the platinum-pemetrexed cohort.

“Osimertinib plus savolitinib provided a statistically significant 45% reduction in the risk of disease progression or death compared with platinum-pemetrexed,” Dr. Lu said.

This PFS advantage was consistent in patients with MET overexpression (median PFS: 8.5 months with osimertinib-savolitinib vs. 5.6 months with platinum-pemetrexed) and MET-amplification (median PFS: 7.6 months with osimertinib-savolitinib vs. 4.2 months with platinum-pemetrexed).

The first interim analysis also revealed positive OS results, with osimertinib plus savolitinib demonstrating an advantage compared with platinum-pemetrexed (median OS: 17.8 months vs. 12.9 months).

“Osimertinib plus savolitinib provided a statistically significant 32% reduction in the risk of death, with a 4.9-month improvement in median OS compared with platinum-pemetrexed,” Dr. Lu said.

The tumor response endpoints also favored osimertinib plus savolitinib. Just over half (51%) of the patients in the osimertinib-savolitinib cohort reported a confirmed objective response, compared to 27% in the platinum-pemetrexed group. Additionally, osimertinib plus savolitinib achieved a median duration of response of 9.7 months versus 5.7 months in the platinum-pemetrexed group.

The osimertinib plus savolitinib combination demonstrated a tolerable safety profile, with no new toxicity signals observed. The median duration of exposure was 8.5 months for patients treated with osimertinib and savolitinib, compared to 3.5 months for those in the platinum-pemetrexed cohort.

Treatment-related adverse events (TRAEs) were similar in both cohorts (93% with osimertinib plus savolitinib vs. 92% with platinum-pemetrexed). Fewer grade 3 or higher TRAEs were observed in the osimertinib plus savolitinib group (40%) compared to the platinum-pemetrexed group (52%).

The most common treatment-emergent adverse events (AEs) in the osimertinib-savolitinib cohort were peripheral edema, anemia, and diarrhea.

In his concluding remarks, Dr. Lu said that these findings establish the clinical value of an all-oral, biomarker-directed treatment approach targeting both EGFR and MET after progression on osimertinib, reinforcing osimertinib as a backbone treatment across all lines of therapy.

“Osimertinib plus savolitinib establishes a new global standard of care for patients with EGFR-mutant advanced NSCLC with MET overexpression and/or amplification after progression on osimertinib,” Dr. Lu said.


About the Authors

Haleigh Behrman

Haleigh Behrman

Assistant Editor, ILCN